Revolade approved for treatment of aplastic anaemia

Revolade (eltrombopag) is the first drug to be licensed in the UK for use in patients with acquired severe aplastic anaemia (SAA) who are either refractory to prior immunosuppressive therapy or heavily pretreated and unsuitable for haematopoietic stem cell transplantation (HSCT).

Further information
View Revolade drug record
Summary of Product Characteristics
Manufacturer: Novartis

The current standard of care for SAA includes immunosuppressive therapy or HSCT. Approximately 40% of patients unresponsive to initial immunosuppressive therapy die from infection or bleeding within five years of their diagnosis. 

Revolade is also indicated in chronic immune thrombocytopenic purpura and in thrombocytopenia in patients with hepatitis C.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more